In just a few years, cannabidiol (CBD) has become immensely popular around the world. First of all, concentrated extracts allow the consumption of a large dose of . hemp is allowed only with the intent to produce fibers or seeds. . Additionally, as many as 26/46 samples (57%) had a THC content > 1%. In , the first cannabinoid receptor was identified (CB1) (Howlett et al ) and . Cannabidiol, a non-euphoriant phytocannabinoid common in certain strains, shares While THC has no activity at vanilloid receptors, CBD, like AEA, is a TRPV1 Initial experiences with medicinal extracts of cannabis for chronic pain. In a clinical trial THC did not have any significant effect on ongoing and . A mixture of mg THC and mg cannabidiol (CBD) lowered spasm .. Cohen C., Perrault G., Voltz C., Steinberg R., Soubrie P. SR, a central cannabinoid (CB(1)) .. Initial experiences with medicinal extracts of cannabis for chronic pain.
had with CBD Has or high (cannabidiol) anyone - any CB experiences with extracts, strains r/cannabis
Mean T max was 7 min smoking , 5 min vapourization , and 2. Mean T max was 7 min smoking , 7 min vapourization , and 2. Mean T max was 13 min smoking , 11 min vapourization , and 2. Mean T max was 13 min smoking , 6 min vapourization , and 2. These findings suggest, among other things, that peak blood THC concentration THC C max was significantly lower after oral consumption compared to either route of inhalation and time to peak blood THC concentration T max occurred significantly later for oral consumption compared to inhalation for both frequent and occasional cannabis smokers.
In addition, C max was significantly higher for the smoking route compared to vapourization, but only among frequent cannabis smokers. In addition, THC C max values were significantly greater among frequent smokers compared to occasional smokers after smoking and vapourization only, and hydroxy-THC C max values were significantly greater among frequent smokers regardless of route of administration.
Oro-mucosal administration of nabiximols is also amenable to self-titration Reference Reference Reference Reference In humans, rectal doses of 2. Cannabinoids are highly hydrophobic, making transport across the aqueous layer of the skin the rate-limiting step in the diffusion process Reference No clinical studies have been published regarding the percutaneous absorption of cannabis-containing ointments, creams, or lotions.
However, some pre-clinical research has been carried out on transdermal delivery of synthetic and natural cannabinoids using a dermal patch Reference Reference Due to its lipophilicity, it is taken up primarily by fatty tissues and highly perfused organs such as the brain, heart, lung, and liver Reference The apparent average volume of distribution of CBD is Pre-clinical studies in mice suggest a more rapid penetration of hydroxy-THC into the brain compared to the parent compound, on the order of 6: This finding lends further support to the evidence on the distribution, accumulation, and storage of THC and metabolites in the adipose tissue and the slow release of THC and metabolites from adipose tissue stores back into the bloodstream Reference Residual THC in plasma likely coming from bodily adipose stores detected weeks after last smoking episode may be associated with persisting psychomotor impairment in frequent chronic cannabis smokers according to the study authors Reference Most cannabinoid metabolism occurs in the liver, and different metabolites predominate depending on the route of administration Reference 78 Reference CBD undergoes extensive Phase I metabolism, with a reported 30 different metabolites in the urine, and the most abundant metabolites are hydroxylated 7 or 11 -carboxy derivatives of CBD, with 7 or 11 -hydroxy CBD as a minor metabolite Reference 78 Reference Reference Xenobiotics are not only metabolized by CYPs but they also modulate the expression level and activity of these enzymes; CYPs are therefore a focal point in drug-drug interactions and adverse drug reactions Reference Please see Section 6.
While few clinical studies have specifically sought to evaluate cannabis-drug interactions per se, many, if not most, studies investigating the therapeutic effects of cannabis e. Cannabis smoking, as well as orally administered dronabinol may also affect the pharmacokinetics of anti-retroviral medications, although no clinically significant short-term impacts on anti-retroviral effects were noted Reference In addition, and as seen with tobacco smoke, cannabis smoke has the potential to induce CYP1A2 thereby increasing the metabolism of xenobiotics biotransformed by this isozyme such as theophylline Reference or the anti-psychotic medications clozapine or olanzapine Reference Further detailed information on drug-drug interactions can be found in Section 6.
Similar results were obtained with intravenous THC administration Reference Following oxidation, the phase II metabolites of the free drug or hydroxylated-THC appear to be glucuronide conjugates Reference Peak plasma values of the psycho-inactive metabolite, norcarboxy THC, occur 1.
The plasma levels of active hydroxy metabolite, achieved through oral administration, are about three times higher than those seen with smoking Reference Concentrations of both parent drug and metabolite peak between approximately 2 to 4 h after oral dosing, and decline over several days Reference A study that characterized cannabinoid elimination in blood from 30 male daily cannabis smokers during monitored sustained abstinence for up to 33 days on a closed residential unit found that low levels approx.
Following oral administration, THC and its metabolites are also excreted in both the feces and the urine Reference 78 Reference A large portion of administered CBD is excreted intact or as its glucuronide Reference Reference Reference The variability in terminal half-life measurements are related to the dependence of this measure on assay sensitivity, as well as on the duration and timing of blood measurements Reference Low levels of THC metabolites have been detected for more than five weeks in the urine and feces of cannabis users Reference Like THC, the decline of CBD levels is also multi-phasic, and the half-life of CBD in humans after smoking has been estimated at 27 - 35 h, and 2 - 5 days after oral administration Reference Reference Reference More limited information is available for inhaled cannabis Reference 58 Reference A dosing interval of 1 h with this dose would give a "continuous high", and the recovery time after the last dose would be min i.
One clinical study reported a peak increase in heart rate and perceived "good drug effect" within 7 min after test subjects smoked a 1 g cannabis cigarette containing either 1. Compared to the placebo, both doses yielded statistically significant differences in subjective and physiological measures; the higher dose was also significantly different from the lower dose for subjective effects, but not physiological effects such as an effect on heart rate.
The equilibration half-life estimate for heart rate was approximately 7 min, but varied between 39 and 85 min for various CNS parameters Reference According to this model, the effects on the CNS developed more slowly and lasted longer than the effect on heart rate.
Subjects reported smoking a mean of one joint per day in the previous 14 days prior to the initiation of the study range: During the study, subjects smoked one cannabis cigarette mean weight 0. According to the authors of the study, the pharmacodynamic-pharmacokinetic relationship displayed a counter-clockwise hysteresis i.
THC , the pharmacological effect is greater at a later time point than at an earlier one for all measured subjective effects e. This particular kind of relationship demonstrates a lack of correlation between blood concentrations of THC and observed effects, beginning immediately after the end of smoking and continuing during the initial distribution and elimination phases.
Following the start of cannabis smoking, heart rate increased significantly at the 30 min time point, diastolic blood pressure decreased significantly only from the 30 min to 1 h time point, and systolic blood pressure and respiratory rate were unaffected at any time. A study that examined the acute subjective effects associated with smoked cannabis at three different doses i.
In addition, the study also showed that higher doses of THC were associated with longer duration of subjective effects.
Findings from the study showed that the time required to reach a maximal "high" rating was slightly delayed 11 - 16 min compared to the time required to reach the peak THC serum concentration. The "high" rating declined after reaching the peak within the first 3. Scores on the VAS for "dizziness", "dry mouth", "palpitations", "impaired memory and concentration", "down", "sedated", and "anxious feelings" reached a maximum within the first 2 h post-dose and these effects were dose-dependent.
With a dose of A dose of Finally, a THC dose of The THC-induced decrease in stimulation i. In fact, sedation was increased by almost six-fold compared to placebo.
The low THC dose was associated with the highest ratings of "like the effects of the drug" and "want more of this drug". Maximal subjective "high" ratings occurred at 60 min following beginning of inhalation.
One clinical study reported that ad libitum vapourization of mg cannabis containing a low-dose 2. Subjective effects were then measured at several time points and effects were correlated with concentrations of cannabinoids in oral fluid and blood.
There were no significant differences between the effects seen with the low 2. Vapourized cannabis significantly increased measures of "stoned" and "sedated" immediately post-dose and lasted 3. Feelings of "anxious" showed significant cannabis-dose effects through 1. Effects and time course of effects were similar between vapourized and smoked cannabis. Another study measured 17 different psychoactive effects as a function of THC dose and time in vapourized cannabis Reference Plasma hydroxy-THC C max for the 2.
The lower dose produced effects lower than that for the high dose and placebo effects were lower than both active doses for "any drug effect", "good drug effect", "high", "impaired", "stoned", "sedated" and "changes perceiving space". For "bad drug effect", "like the drug", "nauseous", "changes perceiving time", ratings with placebo were significantly lower than both active doses.
The higher dose 6. There was a clear dose-response effect for the majority of psychoactive effects. Increases in systolic blood pressure occurred with low 5 mg and high 15 mg oral doses of THC, as well as low 5. In contrast, diastolic blood pressure decreased between 4 and 8 h after dosing. Heart rate increased after all active treatments. A subjective feeling of a "high" was reported to be significantly greater after 15 mg oral THC compared to placebo and to 5 mg oral THC. In contrast, neither the high nor the low doses of oro-mucosal nabiximols were reported to produce a statistically significant subjective "high" feeling.
Study subjects reported being most "anxious" approximately 4 h after administration of 5 mg oral THC, 3 h after 15 mg oral THC, 5. All active drug treatments induced significantly more anxiety compared to placebo.
After 15 mg oral THC, the concentration of THC in plasma was observed to have a weak, but statistically significant, positive correlation with systolic and diastolic blood pressure, "good drug effect", and "high".
After high-dose oro-mucosal nabiximols, positive correlations were also observed between plasma THC concentrations and "anxious", "good drug effect", "high", "stimulated", and M-scale marijuana-scale scores. Consistent with other studies, the authors of this study reported that linear correlations between plasma THC concentrations and physiological or subjective effects were weak. Lastly, although CBD did not appear to significantly modulate the effects of THC, the authors suggested it might have attenuated the degree of the subjective "high".
A dose run-up clinical study looking at the pharmacokinetic and pharmacodynamic profile of supratherapeutic oral doses of THC i.
There was also substantial variability for T max both within and between subjects with an overall median of 3. THC dose-dependently elevated heart rate, and systolic blood pressure dropped at the lower dose i. No changes were noted for diastolic blood pressure. Tolerance, as defined by the Liaison Committee on Pain and Addiction a joint committee with representatives from the American Pain Society, the American Academy of Pain Medicine, and the American Society of Addiction Medicine is a state of adaptation in which exposure to the drug causes changes that result in a diminution of one or more of the drug's effects over time Reference Tolerance to the effects of cannabis or cannabinoids appears to result mostly from pharmacodynamic rather than pharmacokinetic mechanisms Reference Pre-clinical studies indicate that pharmacodynamic tolerance is mainly linked to changes in the availability of the cannabinoid receptors, principally the CB 1 receptor, to signal.
There are two independent but interrelated molecular mechanisms producing these changes: Studies have reported that CB 1 receptors in the caudate-putamen and its projection areas e. CB 1 receptors located in the striatum are also less susceptible to desensitization and downregulation relative to the hippocampus Reference One clinical study showed that chronic cannabis use was associated with a global decrease in CB 1 receptor availability in the brain with significant decreases in CB 1 receptor availability in the temporal lobe, anterior and posterior cingulate cortices, and the nucleus accumbens Reference Furthermore, a couple of clinical studies have examined the time course of changes in the availability of CB 1 receptors following chronic THC administration and abstinence Reference Reference In the second study, cannabis dependence with chronic, moderate daily cannabis smoking was associated with CB 1 receptor downregulation i.
CB 1 receptor downregulation began to reverse rapidly upon termination of cannabis use within two days , and after 28 days of continuous monitored abstinence CB 1 receptor availability was not statistically significantly different from that of healthy controls although CB 1 receptor availability never reached the levels seen with healthy controls.
CB 1 receptor availability was also negatively correlated with cannabis dependence and withdrawal symptoms. The observed regional variations in cellular adaptations to THC in the brain may also generalize to other tissues or organs, explaining why tolerance develops to some of the effects of cannabis and cannabinoids but not to other effects.
In animal models, the magnitude and time-course of tolerance appear to depend on the species, the cannabinoid ligand, the dose and duration of the treatment, and the measures employed to determine tolerance to cannabinoid treatment Reference Tolerance to most of the effects of cannabis and cannabinoids can develop after a few doses, and it also disappears rapidly following cessation of administration Reference Tolerance has been reported to develop to the effects of cannabis on perception, psychoactivity, euphoria, cognitive impairment, anxiety, cortisol increase, mood, intraocular pressure IOP , electroencephalogram EEG , psychomotor performance, and nausea; some have shown tolerance to cardiovascular effects while others have not Reference Reference Reference There is also some evidence to suggest that tolerance can develop to the effects of cannabis on sleep reviewed in Reference As mentioned above, the dynamics of tolerance vary with respect to the effect studied; tolerance to some effects develops more readily and rapidly than to others Reference Reference However, tolerance to some cannabinoid-mediated therapeutic effects i.
According to one paper, in the clinical setting, tolerance to the effects of cannabis or cannabinoids can potentially be minimized by combining lower doses of cannabis or cannabinoids along with one or more additional therapeutic drugs Reference One study reported that tolerance to some of the effects of cannabis, including tolerance to the "high", developed both when THC was administered orally 30 mg; q.
There was no diminution of the appetite-stimulating effect from either route of administration. A clinical study that evaluated the effects of smoked cannabis on psychomotor function, working memory, risk-taking, subjective and physiological effects in occasional and frequent cannabis smokers following a controlled smoking regimen reported that when compared to frequent smokers, occasional smokers showed significantly more psychomotor impairment, more significant impairment of spatial working memory, significantly increased risk-taking and impulsivity, significantly higher scores for "high" ratings, for "stimulated" ratings, and more anxiety Reference Compared with frequent smokers, occasional smokers had significantly increased heart rates relative to baseline and higher systolic and diastolic blood pressure just after dosing.
These findings suggest that frequent cannabis users can develop some tolerance to some psychomotor impairments despite higher blood concentrations of THC. Occasional smokers also reported significantly longer and more intense subjective effects compared with frequent smokers who had higher THC concentrations suggesting tolerance can develop to the subjective effects.
A clinical study evaluated the development of tolerance to the effects of around-the-clock oral administration of THC 20 mg every 3. The morning THC dose increased intoxication ratings on day 2 but had less effects on days 4 after administration of a cumulative mg dose of THC and 6, while THC lowered blood pressure and increased heart rate over the six-day period suggesting the development of tolerance to the subjective intoxicating effects of THC and the absence of tolerance to its cardiovascular effects.
Tolerance to the subjective intoxicating effects of THC administered orally was manifested after a total exposure of mg of THC over the course of four days Reference Another clinical study reported that while heavy chronic cannabis smokers demonstrated tolerance to some of the behaviourally-impairing effects of THC, these subjects did not exhibit cross-tolerance to the impairing effects of alcohol, and alcohol potentiated the impairing effects of THC on measures such as divided attention Reference An uncontrolled, open-label extension study of an initial five-week randomized trial of nabiximols in patients with MS and central neuropathic pain reported the absence of pharmacological tolerance measured by a change in the mean daily dosage of nabiximols to cannabinoid-induced analgesia, even after an almost two-year treatment period in a group of select patients Reference Another long-term, open-label extension study of nabiximols in patients with spasticity caused by MS echoed these findings, also reporting the absence of pharmacological tolerance to the anti-spastic effects measured by a change in the mean daily dosage of nabiximols after almost one year of treatment Reference A multi-centre, prospective, cohort, long-term safety study of patients using cannabis as part of their pain management regimen for chronic non-cancer pain reported small and non-significant increases in daily dose over a one-year study period Reference More recently, a double-blind, placebo-controlled, three-way cross-over clinical study with regular cannabis users suggested that tolerance may not develop towards some of the acute effects on neurocognitive functions despite regular cannabis use Reference One hundred and twenty-two subjects who regularly used cannabis average duration of use: Acute administration of vapourized cannabis impaired performance across a wide range of neurocognitive domains: Frequency of cannabis use correlated significantly with change in subjective intoxication following cannabis administration and also correlated and interacted with changes in psychomotor performance meaning that subjective intoxication and psychomotor impairment following cannabis exposure decreased with increasing frequency of use, however the baseline for subjective intoxication and psychomotor impairment was already higher for frequent users compared to less frequent users likely owing to already elevated THC body burden which can cause sufficient levels of intoxication and mild psychomotor impairment.
The authors suggest that the neurocognitive functions of daily or near daily cannabis users can be substantially impaired from repeated cannabis use, during and beyond the initial phase of intoxication.
Pharmacokinetic tolerance including changes in absorption, distribution, biotransformation and excretion has also been documented to occur with repeated cannabinoid administration, but apparently occurs to a lesser degree than pharmacodynamic tolerance Reference Dependence can be divided into two independent, but in certain situations interrelated concepts: The ECS has been implicated in the acquisition and maintenance of drug taking behaviour, and in various physiological and behavioural processes associated with psychological dependence or addiction Reference 2.
In the former DSM-IV diagnostic and statistical manual of mental disorders fourth edition , the term 'dependence' was closely related to the concept of addiction which may or may not include physical dependence, and is characterized by use despite harm, and loss of control over use Reference There is evidence that cannabis dependence physical and psychological occurs, especially with chronic, heavy use Reference Reference Reference In the new DSM-5, the term "cannabis dependence" has been replaced with the concept of a "cannabis use disorder" CUD which can range in intensity from mild to moderate to severe with severity based on the number of symptom criteria endorsed Reference For a list of symptoms, please refer to the DSM-5 Reference Risk factors for transition from use to dependence have been identified and include being young, male, poor, having a low level of educational attainment, urban residence, early substance use onset, use of another psychoactive substance, and co-occurrence of a psychiatric disorder Reference Notably, the transition to cannabis dependence occurs considerably more quickly than the transition to nicotine or alcohol dependence Reference These increases in both month and lifetime prevalence are thought to be driven by increases in the prevalence of cannabis users.
Higher frequency of cannabis use was associated with greater risk of disorder incidence and prevalence, supporting a dose-response association between cannabis use and risk of substance use disorders. Another study using the U. Survey respondents with month CUD differed significantly from others on all disability components of the survey, with disability increasing significantly, as cannabis disorder severity increased.
Comparing data between the NESARC - Wave 1 and - Wave 2 , one study reported that the prevalence of cannabis use more than doubled between the two waves of the survey Reference Furthermore, there was a large increase in CUD during this intervening time, with nearly 3 out of 10 cannabis users reporting a CUD in - A retrospective study among a nationally representative sample of 6 Australian adults examining the initiation of cannabis use and transition to CUD found that the mean time from first use to the onset of CUD was 3.
Younger age of initiation and other substance use were strong predictors of the transition from use to CUD. Social phobia and panic disorder were also associated with transition from cannabis use to CUD. Male cannabis users had greater risk of CUD than female users, but among women, those with depression were more likely to develop a CUD.
Early-onset of alcohol and daily cigarette smoking were each associated with marked increased risk of early initiation of cannabis use. A handful of clinical studies have examined the differences between men and women with respect to development of dependence, withdrawal symptoms and relapse Reference Physical dependence is most often manifested in the appearance of withdrawal symptoms when use is abruptly halted or discontinued.
Withdrawal symptoms associated with cessation of cannabis use oral or smoked appear within the first one to two days following discontinuation; peak effects typically occur between days 2 and 6 and most symptoms resolve within one to two weeks Reference - Reference Other symptoms appear to include depressed mood, chills, stomach pain, shakiness and sweating Reference Reference Reference Reference Cannabis withdrawal symptoms appear to be moderately inheritable with both genetic and environmental factors at play Reference There are also emerging reports of increased physical dependence with highly potent cannabis extracts e.
There are no approved pharmacotherapies for managing cannabis withdrawal symptoms Reference A range of medications have been explored including antidepressants e. Zolpidem has also been explored as a potential pharmacotherapy to specifically target abstinence-induced disruptions in sleep Reference Reference However, agonist substitution therapy e. Self-titrated doses were lower and showed limited efficacy compared to high fixed doses and subjects typically reported significantly lower ratings of "high" and shorter duration of "high" with nabiximols and placebo compared to smoking cannabis.
A randomized, double-blind, placebo-controlled, six-day, inpatient clinical study of nabiximols as an agonist replacement therapy for cannabis withdrawal symptoms reported that nabiximols treatment attenuated cannabis withdrawal symptoms and improved patient retention in treatment Reference However, placebo was as effective as nabiximols in promoting long-term reductions in cannabis use at follow-up.
Nabiximols treatment significantly reduced the overall severity of cannabis withdrawal symptoms relative to placebo including effects on irritability, depression and craving as well as a more limited effect on sleep disturbance, anxiety, appetite loss, physical symptoms and restlessness.
A placebo-controlled, within-subject, clinical study demonstrated that nabilone 6 - 8 mg daily decreased cannabis withdrawal symptoms including abstinence-related irritability and disruptions in sleep and food intake in daily, non-treatment seeking cannabis smokers Reference It also decreased cannabis self-administration during abstinence in a laboratory model of relapse.
While nabilone did not engender subjective ratings associated with abuse liability i. A follow-up study found that nabilone 3 mg, b. A double-blind, placebo-controlled, week clinical trial testing lofexidine and dronabinol for the treatment of CUD reported no significant beneficial effect compared to placebo for promoting abstinence, reducing withdrawal symptoms, or retaining individuals in treatment Reference in contrast to a previous study that showed efficacy of 40 mg dronabinol daily vs.
A recent systematic review of the evidence of CBD as an intervention for addictive behaviours reported that to date, only 14 studies have been conducted, the majority in animals with only a handful in humans Reference The limited number of pre-clinical studies carried out to date suggest that CBD may have therapeutic potential for the treatment of opioid, cocaine and psychostimulant addiction, and some preliminary data suggest CBD may also be beneficial in cannabis and tobacco addiction in humans Reference The limited number of pre-clinical studies published thus far suggest CBD may have an impact on the intoxication and relapse phase of opioid addiction, while CBD does not appear to have an impact on the rewarding effects of stimulants e.
With respect to cannabis dependence, pre-clinical studies show that CBD is not reinforcing on its own, but its impact on cannabis-related dependence behaviour remains unclear Reference In one clinical study, a 19 year-old female with cannabis dependence exhibiting cannabis withdrawal symptoms upon cannabis cessation was administered up to mg of CBD range: In another human study, cannabis with a higher CBD to THC ratio was associated with lower ratings of pleasantness for drug stimuli explicit "liking" , but no group difference in "craving" or "stoned" ratings was noted Reference Reference However, a multi-site, double-blind, placebo-controlled study demonstrated that CBD - mg had no effect on subjective ratings associated with cannabis abuse liability Reference A randomized, double-blind, crossover clinical study in 10 healthy volunteers examining the effects of CBD on the intoxication phase of alcohol addiction reported no differences in feelings of "drunk", "drugged", or "bad" between the alcohol only and the alcohol and CBD groups Reference Reference No pre-clinical studies exist on the use of CBD for hallucinogen-, sedative-, tobacco-, or alcohol-addictive behaviours and no human studies exist on the use of CBD for opioid-, psychostimulant-, hallucinogen-, or sedative-addictive behaviours Reference The ECS is present in early development, is critical for neurodevelopment and maintains expression in the brain throughout life Reference Furthermore, the ECS undergoes dynamic changes during adolescence with significant fluctuations in both the levels and locations of the CB 1 receptor in the brain as well as changes in the levels of the endocannabinoids 2-AG and anandamide Reference The dynamic changes occurring in the ECS during adolescence also overlap with a significant period of neuronal plasticity that includes neuronal proliferation, rewiring and synaptogenesis, and dendritic pruning and myelination that occurs at the same time Reference This period of significant neuroplasticity does not appear to be complete until at least the age of 25 Reference Thus, this neurodevelopmental time window is critical for ensuring proper neurobehavioural and cognitive development and is also influenced by external stimuli, both positive and negative e.
Based on the available scientific evidence, youths are more susceptible to the adverse effects associated with cannabis use, especially chronic use Reference Reference Studies examining non-medical use of cannabis strongly suggest early onset i. Based on the current available evidence, it is unclear for how long some or all of the neurocognitive effects persist following cessation of use. Some investigators have found certain cognitive deficits to persist for up to one year or longer after cannabis cessation, while others have demonstrated a far shorter period of recovery i.
Though the data from human studies do not establish causality solely from cannabis use, the pre-clinical studies in animals do indicate that adolescent exposure to cannabinoids can catalyze molecular processes leading to functional deficits in adulthood - deficits that are not found following adult exposure to cannabis. The authors note that definitive conclusions cannot be made yet as to whether cannabis use - on its own - negatively impacts the adolescent brain, and future research can help elucidate this relationship by integrating assessments of molecular, structural, and behavioral outcomes Reference Factors that may influence persistence of cognitive deficits can include age at onset of use, frequency and duration of use, co-morbidities, and use of other drugs tobacco, alcohol, and other psychoactive drugs.
While adverse effects associated with THC-predominant cannabis use in youth have been well documented, far less is known about the adverse effects associated with CBD-predominant cannabis use. Nevertheless, as mentioned above, the ECS plays important roles in nervous system development in utero as well as during youth see Section 7.
There is evidence to suggest that like the changes seen with the ECS during development and adolescence, there are changes in the ECS associated with ageing.
In addition, the coupling of CB 1 receptors to G proteins is also reduced in specific brain areas in older animals Reference Age-related changes in the expression of components of the ECS appear similar in rodents and humans Reference Disruption of CB receptors appears to enhance age-related decline of a number of tissues suggesting an important role for the ECS in the control of the ageing process Reference In general, the elderly may be more sensitive to the effects of drugs acting on the CNS Reference A number of physiological factors may lie at the root of this increased sensitivity such as: There is very little information available on the effects of cannabis and cannabinoids in geriatric populations and based on current levels of evidence, no firm conclusions can be made with regard to the safety or efficacy of cannabinoid-based drugs in elderly patients but see below for one of the few clinical studies of safety carried out specifically in geriatric populations Reference Reference Reference Furthermore, as cannabinoids are lipophilic, they may tend to accumulate to a greater extent in elderly individuals since such individuals are more likely to have an increase in adipose tissue, a decrease in lean body mass and total body water, and an increase in the volume of distribution of lipophilic drugs Reference Lastly, age-related changes in hepatic function such as a decrease in hepatic blood flow and slower hepatic metabolism can slow the elimination of lipophilic drugs and increase the likelihood of adverse effects Reference A randomized, double-blind, placebo-controlled, cross-over clinical trial that evaluated the pharmacokinetics of THC in 10 older patients with dementia mean age 77 years over a week period reported that the median time to reach maximal concentration in the blood T max was between 1 and 2 h with THC pharmacokinetics increasing linearly with increasing dose but with wide inter-individual variation Reference Only one clinical study has thus far been carried out looking specifically at the safety of THC in an elderly population.
In this study, 12 adults aged 65 and older who were deemed to be healthy were included, and exclusion criteria included high falls risk, regular cannabis use, history of sensitivity to cannabis, drug and alcohol abuse, compromised cardiopulmonary function, and psychiatric comorbidities.
The most commonly reported health problems were hypertension and hypercholesterolemia and subjects reported using an average of 2 medications e. Adverse events first occurred within 20 min of dosing, with all adverse events occurring between 55 and min after dosing and resolving completely within 3.
No moderate or serious adverse events were reported in this trial. While this clinical study adds important information regarding the safety and tolerability of THC in a healthy elderly population, additional studies are needed to evaluate the safety and tolerability of cannabis and cannabinoids in elderly populations having various co-morbidities.
In humans, sex-dependent differences have been often observed in the biological and behavioural effects of substances of abuse, including cannabis Reference In male animals, higher densities of CB 1 receptors have been observed in almost all cerebral regions analyzed whereas in females a more efficient coupling of the CB 1 receptor to downstream G-protein signaling has been observed Reference In humans, sex differences in CB 1 receptor density have also been reported, with men having higher receptor density compared to women Reference Table 1 Results RCTs of cannabinoids in treatment of pain syndromes.
Practical issues with cannabinoid medicines Phytocannabinoids are lipid soluble with slow and erratic oral absorption. Broad experience with pain sparks search for relief [online] Short-term effects of cannabinoids in patients with HIV-1 infection. A randomized, placbo-controlled clinical trial. Cannabis in painful HIV-associated sensory neuropathy: Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors.
Cannabinoid CB1 receptor activation inhibits trigeminovascular neurons. J Pharmacol Exp Ther. Anandamide is able to inhibit trigeminal neurons using an in vivo model of trigeminovascular-mediated nociception. Anandamide acts as a vasodilator of dural blood vessels in vivo by activating TRPV1 receptors.
Are oral cannabinoids safe and effective in refractory neuropathic pain? Cannflavin A and B, prenylated flavones from Cannabis sativa L. Anti-inflammatory activity of oleoresin from Brazilian Copaifera. Effects of nabilone, a synthetic cannabinoid, on postoperative pain: Experience with the synthetic cannabinoid nabilone in chronic noncancer pain. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: Molecular targets for cannabidiol and its synthetic analogues: Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine Sativex in the treatment of pain caused by rheumatoid arthritis.
Rheumatology Oxford ; Therapeutic uses of cannabis. Harwood Academic Publishers; Analgesic and reinforcing proerties of delta9-THC-hemisuccinate in adjuvant-arthritic rats. Journal of Cannabis Therapeutics. Review of the validity and significance of cannabis withdrawal syndrome. Lack of analgesic efficacy of oral deltatetrahydrocannabinol in postoperative pain. Inhibition of biosynthesis by the naturally occurring cannabinoids. Russo EB, Grotenhermen F, editors.
Pharmacology, toxicology and therapeutic potential. Abuse potential of dronabinol Marinol J Psychoactive Drugs. Are cannabinoids an effective and safe option in the management of pain? A qualitative systematic review.
Inhibition of an equilibrative nucleoside transporter by cannabidiol: In vitro experiment optimization for measuring tetrahydrocannabinol skin permeation. Enhancement of mu opioid antinociception by oral delta9-tetrahydrocannabinol: Dose-response analysis and receptor identification. Antinociceptive synergy between delta 9 -tetrahydrocannabinol and opioids after oral administration.
Modulation of oral morphine antinociceptive tolerance and naloxone-precipitated withdrawal signs by oral Delta 9-tetrahydrocannabinol. Neurobehavioral actions of cannabichromene and interactions with delta 9-tetrahydrocannabinol. The breeding of cannabis cultivars for pharmaceutical end uses. Medicinal uses of cannabis and cannabinoids.
Testing hypotheses about the relationship between cannabis use and psychosis. Isolation and structure of a brain constituent that binds to the cannabinoid receptor.
Antihyperalgesic properties of the cannabinoid CT-3 in chronic neuropathic and inflammatory pain states in the rat. Potency trends of delta9-THC and other cannabinoids in confiscated marijuana from — Standardized cannabis extract in the treatment of postherpetic neuralgia: The separation of central from peripheral effects on a structural basis.
Opiate, cannabinoid, and eicosanoid signaling converges on common intracellular pathways nitric oxide coupling. Prostaglandins Other Lipid Mediat.
DEA, Congress, and the courts, oh my! Coxibs and cardiovascular disease. N Engl J Med. The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Schizophrenia, depression, and anxiety. Taylor and Francis; Affective, behavior and cognitive disorders in the elderly with chronic musculoskelatal pain: Isolation, structure and partial synthesis of an active constituent of hashish.
J Am Chem Soc. International Cannabinoid Research Society; Cannabigerol behaves as a partial agonist at both CB1 and CB2 receptors; p. Flavonoids inhibit cytokine-induced endothelial cell adhesion protein gene expression. Screening of plant extracts for new CB2-selective agonists revewals new players in Cannabis sativa ; p.
IASP global year against pain in older persons: Cannabis vaporizer combines efficient delivery of THC with effective suppression of pyrolytic compounds. Comparative study of different essential oils of Bupleurum gibraltaricum Lamarck.
Study of the topical anti-inflammatory activity of Achillea ageratum on chronic and acute inflammation models. Z Naturforsch [C] ; Medical use of cannabis in the Netherlands. Marihuana, the forbidden medicine. Yale University Press; Pharmacokinetics and pharmacodynamics of cannabinoids. Cannabinoids for therapeutic use: American Journal of Drug Delivery. Findings and recommendations by an expert panel.
Developing science-based per se limits for driving under the influence of cannabis DUIC p. Guy GW, Robson P. A Phase I, double blind, three-way crossover study to assess the pharmacokinetic profile of cannabis based medicine extract CBME administered sublingually in variant cannabinoid ratios in normal healthy male volunteers GWPK Journal of Cannabis Therapeutics. Cannabidiol and - Delta9-tetrahydrocannabinol are neuroprotective antioxidants.
Evaluation of a vaporizing device Volcano for the pulmonary administration of tetrahydrocannabinol. Cannabinoid receptor localization in brain. Pre- and postsynaptic distribution of cannabinoid and mu opioid receptors in rat spinal cord.
Inhibition of noxious stimulus-evoked activity of spinal cord dorsal horn neurons by the cannabinoid WIN 55, An endocannabinoid mechanism for stress-induced analgesia. A multicenter dose-escalation study of the analgesic and adverse effects of an oral cannabis extract Cannador for postoperative pain management.
Nonclassical cannabinoid analgetics inhibit adenylate cyclase: Medicinal gebruik van cannabis.: Johnson JR, Potts R. Cannabis-based medicines in the treatment of cancer pain: Clinical studies of cannabis tolerance and dependence. Ann N Y Acad Sci. Assessing the science base. Institute of Medicine; Attenuation of allergic contact dermatitis through the endocannabinoid system. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: Cannabinoid influence on cytokine profile in multiple sclerosis.
Cannabis potency in Europe. Local administration of delta9-tetrahydrocannabinol attenuates capsaicin-induced thermal nociception in rhesus monkeys: Psychopharmacology Berl ; Mini Rev Med Chem.
Pharmacokinetics, metabolism and drug-abuse potential of nabilone. The cannabinoid receptor agonist WIN 55, mesylate blocks the development of hyperalgesia produced by capsaicin in rats.
Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. Activation and binding of peroxisome proliferator-activated receptor gamma by synthetic cannabinoid ajulemic acid. Myrcene mimics the peripheral analgesic activity of lemongrass tea. A case series of patients using medicinal marihuana for management of chronic pain under the Canadian Marihuana Medical Access Regulations.
J Pain Symptom Manage. Cannabinoid receptors as therapeutic targets. Ann Rev Pharmacol Toxicol. The synthetic cannabinoid nabilone improves pain and symptom management in cancer patietns. Breast Cancer Res Treat. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis.
Chronic administration of cannabinoids regulates proenkephalin mRNA levels in selected regions of the rat brain. Brain Res Mol Brain Res. Suppression of noxious stimulus-evoked activity in the ventral posterolateral nucleus of the thalamus by a cannabinoid agonist: Correlation between electrophysiological and antinociceptive effects.
Endocannabinoids and the gastrointestinal tract. Cannabis and cannabis extracts: Greater than the sum of their parts? Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. DeltaTHC and other cannabinoids content of confiscated marijuana: Cannabinoids in MS - are we any closer to knowing how best to use them? The endocannabinoid pathway in Huntington's disease: Cannabinoid system and neuroinflammation: Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: Neuroprotective cannabinoid receptor antagonist SRA prevents downregulation of excitotoxic NMDA receptors in the ischemic penumbra.
Dexanabinol HU in the treatment of severe closed head injury: Efficacy and safety of dexanabinol in severe traumatic brain injury: Cannabinoid-based drugs as anti-inflammatory therapeutics. Anti-inflammatory property of the cannabinoid agonist WIN in a rodent model of chronic brain inflammation. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice.
Involvement of the cannabimimetic compound, N-palmitoyl-ethanoIamine, in inflammatory and neuropathic conditions: Review of the available pre-clinical data, and first human studies. Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption.
Effect of the cannabinoid CB1 receptor antagonist rimonabant on nociceptive responses and adjuvant-induced arthritis in obese and lean rats. CB1 cannabinoid receptor signalling in Parkinson's disease. The cannabinoid receptor agonist WIN 55, reduces D2, but not D1, dopamine receptor-mediated alleviation of akinesia in the reserpine-treated rat model of Parkinson's disease.
Effects of levodopa on endocannabinoid levels in rat basal ganglia: Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease. High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients.
Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: DeIta9-tetrahydrocannabinol improves motor control in a patient with musician's dystonia.
Cannabis for dyskinesia in Parkinson disease: Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia. Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease.
Survey on cannabis use in Parkinson's disease: AIsasua del Valle A. Implication of cannabinoids in neurological diseases. An overview of Parkinson's disease and the cannabinoid system and possible benefits of cannabinoid-based treatments. Potential role of cannabinoids in Parkinson's disease.
The pattern of neurodegeneration in Huntington's disease: Selective vulnerability in Huntington's disease: Loss of cannabinoid receptors in the substantia nigra in Huntington's disease.
Arvanil, a hybrid endocannabinoid and vanilloid compound, behaves as an antihyperkinetic agent in a rat model of Huntington's disease. The cannabinoid receptor agonist WIN 55, attenuates the effects induced by quinolinic acid in the rat striatum.
Controlled clinical trial of cannabidiol in Huntington's disease. Cannabinoids reduce symptoms of Tourette's syndrome. Delta 9-tetrahydrocannabinol THC is effective in the treatment of tics in Tourette syndrome: Tourette syndrome is not caused by mutations in the central cannabinoid receptor CNR1 gene. Marijuana in the management of amyotrophic lateral sclerosis.
Am J Hosp Palliat Care. Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice. AM , a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis. The CB2 cannabinoid agonist AM prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset.
Survey of cannabis use in patients with amyotrophic lateral sclerosis. A molecular link between the active component of marijuana and Alzheimer's disease pathology. Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease. Int J Geriatr Psychiatry. DeItatetrahydrocannabinol for nighttime agitation in severe dementia. Anticonvulsant activity of four oxygenated cannabidiol derivatives.
Res Commun Chem Pathol Pharmacol. Antiepileptic potential of cannabidiol analogs. Structure-anticonvulsant activity relationships of cannabidiol analogs. Anticonvulsant effect of cannabidiol. S Afr Med J. Cannabidiol-antiepileptic drug comparisons and interactions in experimentally induced seizures in rats.
Anticonvulsant interaction of cannabidiol and ethosuximide in rats. Potential therapeutical effects of cannabidiol in children with pharmacoresistant epilepsy. Cannabinoid CB1 receptor antagonists cause status epilepticus-Iike activity in the hippocampal neuronal culture model of acquired epilepsy. Arachidonyl-2'-chIoroethyIamide, a highly selective cannabinoid CB1 receptor agonist, enhances the anticonvulsant action of valproate in the mouse maximal electroshock-induced seizure model.
Grand mal convulsions subsequent to marijuana use. Chronic administration of cannabidiol to healthy volunteers and epileptic patients.
Cannabinoids in bipolar affective disorder: The use of cannabis as a mood stabilizer in bipolar disorder: Towards a cannabinoid hypothesis of schizophrenia: Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: Impact of cannabis use.
Clinical features of cannabis psychosis in schizophrenia patients. Cannabis and acute psychosis. Schizophrenia and cannabis consumption: A comparison of symptoms and family history in schizophrenia with and without prior cannabis use: Implications for the concept of cannabis psychosis. Lifetime positive symptoms in patients with schizophrenia and cannabis abuse are partially explained by co-morbid addiction. Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder.
Antipsychotic effect of cannabidiol. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz J Med Biol Res. Cannabidiol monotherapy for treatment-resistant schizophrenia.
Enhancing cannabinoid neurotransmission augments the extinction of conditioned fear. Inhibition of fatty-acid amide hydrolase accelerates acquisition and extinction rates in a spatial memory task. Differential response to acute and repeated stress in cannabinoid CB1 receptor knockout newborn and adult mice. Drug use and validity of substance use self-reports in veterans seeking help for posttraumatic stress disorder.
Depression in Parkinson's disease is related to a genetic polymorphism of the cannabinoid receptor gene CNR1. Antianxiety effect of cannabidiol in the elevated plus-maze. Anxiolytic effect of cannabidiol derivatives in the elevated plus-maze. A single dose study of nabilone, a synthetic cannabinoid. The efficacy and safety of nabilone a synthetic cannabinoid in the treatment of anxiety.
The effects of marijuana on human sleep patterns. Effects of marihuana on sleeping states. Effects of marijuana extract and tetrahydrocannabinol on electroencephalographic sleep patterns. Effects of high dosage deItatetrahydrocannabinol on sleep patterns in man.
Effect of Deltatetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults. Effects of smoked marijuana in experimentally induced asthma. Am Rev Respir Dis. Respiratory status of seventy-four habitual marijuana smokers.
Effect of oral administration of delta-tetrahydrocannabinol on airway mechanics in normal and asthmatic subjects. Acute effects of smoked marijuana and oral deltatetrahydrocannabinol on specific airway conductance in asthmatic subjects. Acute pulmonary physiologic effects of smoked marijuana and oral 9 -tetrahydrocannabinol in healthy young men. Acute and subacute bronchial effects of oral cannabinoids.
Bronchodilator effect of deltaltetrahydrocannabinol. Br J Clin Pharmacol. Bronchodilator effect of deltaltetrahydrocannabinol administered by aerosol of asthmatic patients.
Cardiovascular effects of intravenous deltatetrahydrocannabinol: The effects of deItatetrahydrocannabinol cannabis on cardiac performance with and without beta blockade. Short-term effects of smoked marihuana on left ventricular function in man. Cardiovascular effects of prolonged delta-9tetrahydrocannabinol ingestion. Cardiovascular and metabolic considerations in prolonged cannabinoid administration in man.
The cannabinoid CB1 receptor antagonist rimonabant attenuates the hypotensive effect of smoked marijuana in male smokers. Cannabinoids in glaucoma II: Soft cannabinoid analogues as potential anti-glaucoma agents. Comparison of the enzymatic stability and intraocular pressure effects of 2-arachidonylglycerol and noladin ether, a novel putative endocannabinoid. Invest Ophthalmol Vis Sci. Effect of the enzyme inhibitor, phenylmethylsulfonyl fluoride, on the IOP profiles of topical anandamides.
Ophthalmic arachidonylethanolamide decreases intraocular pressure in normotensive rabbits. Brain Res Mol Brain Res. Ocular hypotension, ocular toxicity, and neurotoxicity in response to marihuana extract and cannabidiol.
Intraocular pressure, ocular toxicity and neurotoxicity after administration of cannabinol or cannabigerol. Intraocular pressure, ocular toxicity and neurotoxicity after administration of delta 9-tetrahydrocannabinol or cannabichromene. Marihuana smoking and intraocular pressure. Topical delta 9-tetrahydrocannabinol in hypertensive glaucomas.
Topical delta 9-tetrahydrocannabinol and aqueous dynamics in glaucoma. Effect of marihuana on intraocular and blood pressure in glaucoma. DeIta 9 -tetrahydrocannabinoI, euphoria and intraocular pressure in man. Effects of tetrahydrocannabinol on arterial and intraocular hypertension. IntJ Clin Pharmacol Biopharm. Effect of sublingual application of cannabinoids on intraocular pressure: Mini Rev Med Chem. Endocannabinoids as emerging suppressors of angiogenesis and tumor invasion review. Cannabinoids induce glioma stem-like cell differentiation and inhibit gliomagenesis.
The nonpsychoactive cannabidiol triggers caspase activation and oxidative stress in human glioma cells. Cannabinoid receptors as novel targets for the treatment of melanoma. Delta9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation.
Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes. Delta9-tetrahydrocannabinol-induced apoptosis in Jurkat leukemia T cells is regulated by translocation of Bad to mitochondria. Cannabidiol-induced apoptosis in human leukemia cells: A novel role of cannabidiol in the regulation of p22phox and Nox4 expression. The cannabinoid CB1 receptor antagonist rimonabant SR inhibits human breast cancer cell proliferation through a lipid raft-mediated mechanism.
A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. The molecular mechanisms of morphine addiction. A review of the current literature. Benzodiazepine use, abuse, and dependence.
Clinical manifestations of transdermal scopolamine addiction. Ear Nose Throat J. A review of the nonmedical use of ketamine: The nonmedical use of ketamine, part two: A review of problem use and dependence. Parkinson's disease, reward deficiency syndrome and addictive effects of levodopa].
The science of stimulant abuse. Cannabinoid receptor type 2 gene is associated with human osteoporosis. Peripheral cannabinoid receptor, CB2, regulates bone mass.
Evidence for novel cannabinoid receptors. Milk intake and survival in newborn cannabinoid CB1 receptor knockout mice:
There was a problem providing the content you requested
Dietary supplements containing varying amounts of CBD have been touted as Adams and Alexander R. Todd—Mechoulam's interest was piqued by anecdotal stock, labs, and they were extracting cannabidiol and other cannabis . High- CBD strains of cannabis and other CBD-based products are. CBD oil is made by extracting CBD from the cannabis plant, then Studies have shown that CBD may help reduce chronic pain by and THC in people with cancer-related pain who did not experience High blood pressure is linked to higher risks of a number of health Are There Any Side Effects?. But what evidence do we have regarding cannabis and its effects on sleep? Currently research on the medicinal use of cannabis is restricted due to the legal THC can cause anxiety reactions but higher concentrations of cannabidiol may Certainly anyone who has used alcohol to help sleep knows that in the long run.